Relationship between plasma fibrinogen degradation products(FDP) and D-dimer levels and disease activity in rheumatoid arthritis: A STROBE compliant article

Qiang, FuYong; Xu, Hui; Sawada, Jun

doi:10.1097/md.0000000000030455

Cited by 4 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asthmatic patients revealed strong positive associations between fibrinogen and both ESR and pre-treatment CRP, while YKL-40 appeared to be independent of the other variables analyzed. These findings may reflect the well-known fact that fibrinogen, CRP, and ESR are general markers of systemic inflammation and tend to be directly related to each other even in healthy subjects [ 41 , 42 ]. The most significant correlations in COPD patients were, by contrast, found for YKL-40; that is, negative association with lymphocyte-related parameters and positive, but weaker association with neutrophil-related parameters.…”

Section: Discussionmentioning

confidence: 78%

Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are not only common obstructive respiratory conditions but also major causes of morbidity and mortality worldwide. There is, however, a surprising lack of blood-based biomarkers for separating between these pulmonary disorders. The aim of this study was to assess the practical relevance of using serum YKL-40, single or combined, for this purpose. Materials and Methods: Subjects included Romanian patients with BA (n = 24) or COPD (n = 27). YKL-40, fibrinogen, pre-treatment C-reactive protein (CRP), post-treatment CRP, erythrocyte sedimentation rate, interleukin 6 (IL-6), procalcitonin (PCT), absolute neutrophil count, neutrophil percentage, absolute lymphocyte count, lymphocyte percentage, absolute eosinophil count, and eosinophil percentage were measured and compared between these patients. Results: This is the first study investigating the clinical significance of serum YKL-40 in delineating between COPD and BA in Caucasian populations. Only fibrinogen and YKL-40 levels were different between COPD and BA, with the measured values being significantly elevated. These patients exhibited distinct inflammatory profiles. Using the upper quartiles of these variables for the pooled study population (YKL-40: 5100 pg/mL; fibrinogen: 552 mg/dL) as cut-off values, subjects were classified into high or low groups. High YKL-40 adults revealed significantly increased PCT levels. High fibrinogen subjects, by contrast, showed significantly elevated IL-6 concentrations and pre-treatment CRP levels. Low YKL-40 and fibrinogen patients showed the absence of COPD. Conclusions: Combined use of serum YKL-40 and fibrinogen may be useful for identifying the absence of COPD.

show abstract

Section: Discussionmentioning

confidence: 78%

Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The 31 selected studies, including a total of 36 group comparators, assessed the D-dimer in 2724 RD patients (mean age 46 years, 75% females) and 3437 healthy controls 62,63,66,75,79,80,[82][83][84][85][86][88][89][90][91][92] Europe (n = 12), 64,[67][68][69][70][71][72][73][74][76][77][78] America (n = 2), 81,87 and Oceania (n = 1). 65 RA was investigated in 10 study groups, [66][67][68][69][70][71]73,79,88,91 SLE in nine, 66,72,75,[81][82][83]86,87,89 BD in three,…”

Section: Resultsmentioning

confidence: 99%

“…65 RA was investigated in 10 study groups, [66][67][68][69][70][71]73,79,88,91 SLE in nine, 66,72,75,[81][82][83]86,87,89 BD in three, 62,76,77 AAV in three, 78,83,84 spondyloarthritis (SpA) and AS in three, 70,85,90 SSc in two, 64,74 OA in two, 65,70 gout in one, 80 crystal arthritis in one, 70 Takayasu arteritis (TA) in one, 63 and primary Sjögren's Syndrome (pSS) in one. 92 Twenty-four studies were prospective [62][63][64][65][66][67][68][69][70][71][73][74][75]…”

Section: Resultsmentioning

confidence: 99%

“…The continents where the studies were conducted included Asia ( n = 16), 62,63,66,75,79,80,82–86,88–92 Europe ( n = 12), 64,67–74,76–78 America ( n = 2), 81,87 and Oceania ( n = 1) 65 . RA was investigated in 10 study groups, 66–71,73,79,88,91 SLE in nine, 66,72,75,81–83,86,87,89 BD in three, 62,76,77 AAV in three, 78,83,84 spondyloarthritis (SpA) and AS in three, 70,85,90 SSc in two, 64,74 OA in two, 65,70 gout in one, 80 crystal arthritis in one, 70 Takayasu arteritis (TA) in one, 63 and primary Sjögren's Syndrome (pSS) in one 92 . Twenty‐four studies were prospective 62–71,73–79,81,83–85,87,91,92 and the remaining seven retrospective 72,80,82,86,88–90 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and meta‐analysis of the association between the D‐dimer and rheumatic diseases

Zinellu,

Mangoni

2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionThere is good evidence that specific autoimmune rheumatic diseases (RDs), for example, rheumatoid arthritis and systemic lupus erythematosus (SLE), are associated with a state of hypercoagulability and an increased risk of venous thromboembolism (VTE). However, limited information regarding this association is available for other autoimmune or autoinflammatory RDs. We sought to address this issue by conducting a systematic review and meta‐analysis of the association between the d‐dimer, an established marker of hypercoagulability and VTE, and RDs and the possible clinical and demographic factors mediating this association.MethodsWe searched the electronic databases PubMed, Web of Science, and Scopus from inception to January 31, 2024. The risk of bias and the certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and GRADE, respectively.ResultsIn 31 studies selected for analysis (2724 RD patients and 3437 healthy controls), RD patients had overall significantly higher d‐dimer concentrations when compared to controls (standard mean difference = 0.93, 95% CI 0.76−1.10, p < .001; I2 = 86.1%, p < .001; moderate certainty of evidence). The results were stable in a sensitivity analysis. Significant associations were observed between the effect size of the between‐group differences in d‐dimer concentration and age, specific RD and RD category, RD duration, fibrinogen, plasminogen activator inhibitor, C‐reactive protein, and erythrocyte sedimentation rate.ConclusionsOverall, patients with RDs have significantly higher d‐dimer concentrations when compared with healthy controls, indicating a state of hypercoagulability. The alterations in d‐dimer concentrations are mediated by age, specific RD and RD category, RD duration, and markers of anticoagulation and inflammation. Further research is warranted to investigate d‐dimer concentrations across the spectrum of RDs and their utility in predicting and managing VTE in these patients (PROSPERO registration number: CRD42024517712).

show abstract

“…Several investigators have confirmed the correlation between D-dimer levels and rheumatoid arthritis activity indices through retrospective data mining [ 26 ]. In addition to its predictive value for the diagnosis of VTE in CTD patients [ 27 ], it has been shown that D-dimer level is also a valid serologic index for assessing disease activity in some CTD patients [ 28 , 29 ]. D-dimer can be used as one of the effective monitoring indicators during the suppression of hypercoagulability due to immune activity with glucocorticoids.…”

Section: Vte Associated With the Systemic Inflammatory Responsementioning

confidence: 99%

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Jiang,

Jia,

Dong

2024

Thrombosis J

View full text Add to dashboard Cite

As an autoimmune disease, the persistent systemic inflammatory response associated with connective tissue disease (CTD) is involved in the development of venous thromboembolism (VTE). However, clinical data showed that the risk of VTE in patients differed between subtypes of CTD, suggesting that different subtypes may have independent mechanisms to promote the development of VTE, but the specific mechanism lacks sufficient research at present. The development of pulmonary fibrosis also contributes to the development of VTE, and therefore, patients with CTD-associated interstitial lung disease (CTD-ILD) may be at higher risk of VTE than patients with CTD alone or patients with ILD alone. In addition, the activation of the coagulation cascade response will drive further progression of the patient’s pre-existing pulmonary fibrosis, which will continue to increase the patient’s risk of VTE and adversely affect prognosis. Currently, the treatment for CTD-ILD is mainly immunosuppressive and antirheumatic therapy, such as the use of glucocorticoids and janus kinase-inhibitors (JAKis), but, paradoxically, these drugs are also involved in the formation of patients’ coagulation tendency, making the clinical treatment of CTD-ILD patients with a higher risk of developing VTE challenging. In this article, we review the potential risk factors and related mechanisms for the development of VTE in CTD-ILD patients to provide a reference for clinical treatment and prevention.

show abstract

Relationship between plasma fibrinogen degradation products(FDP) and D-dimer levels and disease activity in rheumatoid arthritis: A STROBE compliant article

Cited by 4 publications

References 26 publications

Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study

Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study

A systematic review and meta‐analysis of the association between the D‐dimer and rheumatic diseases

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Contact Info

Product

Resources

About